Eko, a cardiopulmonary digital health company, has launched the next-generation Eko DUO. DUO is the first U.S. Food and Drug Administration (FDA)-cleared cardiac assessment tool that functions as an electrocardiogram (ECG) and digital stethoscope to detect early signs of heart disease and facilitate timely care and personalized disease management.
Clinicians use the pocket-sized Eko DUO to better inform care decisions by getting more cardiac information at a glance without disrupting their workflow or running costly tests. Purpose-built for wireless listening and recording—both in-person and via telehealth—DUO is ideal for clinicians who need to be mobile or work outside of normal clinical environments. Its unobtrusive form factor makes it easy for clinicians to deliver care in both clinical and non-clinical environments like residential care facilities or a patient’s own home.
Eko’s automated disease detection software, powered by FDA-cleared, clinically-proven artificial intelligence (AI) algorithms, helps clinicians detect heart murmurs and atrial fibrillation with comparable accuracy to human experts. Most recently, real-world validation for Eko’s heart murmur detection algorithm came from a peer-reviewed publication in the Journal of the American Heart Association.